Premium
Successful hematopoietic cell transplantation in Fanconi anemia patients with renal impairment using ultra‐reduced doses of cyclophosphamide and fludarabine
Author(s) -
Ayas Mohamad Fekredeen,
AlSeraihi Amal,
AlAgil Amal,
AlAhmari Ali,
Ghemlas Ibrahim,
Ayas Mouhab
Publication year - 2018
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27371
Subject(s) - medicine , fanconi anemia , fludarabine , transplantation , hematopoietic stem cell transplantation , cyclophosphamide , regimen , oncology , savior sibling , anemia , haematopoiesis , population , gastroenterology , chemotherapy , stem cell , dna repair , biochemistry , chemistry , genetics , environmental health , biology , gene
Hematopoietic cell transplantation (HCT) remains until now the only curative modality for hematological manifestations in patients with Fanconi anemia (FA). The doses of alkylating agents used in the conditioning of this patient population before HCT are usually significantly decreased due to the genomic instability of the FA cells. FA patients with renal impairment represent a dilemma because of the need to further modify the conditioning regimen according to the degree of renal impairment to avoid additional toxicity. At our institution, we successfully transplanted three FA patients using an ultra‐modified regimen.